@article{oai:shiga-med.repo.nii.ac.jp:00000064,
 author = {澤井, 聡 and SAWAI, Satoru and KONTANI, Keiichi and 紺谷, 桂一 and 花岡, 淳 and HANAOKA, Jun and 森, 渥視 and MORI, Atsumi},
 journal = {滋賀医科大学雑誌},
 month = {Feb},
 note = {MUC-1 mucin has been reported to carry a strong immunogenicity and to be recognized by Tlymphocytes in MHC-unrestricted manner. Also, the antigenic epitopes of this molecule are known to be locatedwithin the tandem repeat domain of MUC-1 core protein. In this study, we analyzed the ability of 30-amino acid oligopeptides (MUC-1 peptide) derived from the MUC-1 core to elicit tumor-specific CTLs in peripheralblood mononuclear cells (PBMCs) from patients with lung cancer. To determine whether the MUC-1 peptide was presented by antigen presenting cells, peptides bound on the dendritic cells (DCs) pulsedwith the MUC-1 peptide were eluted by acid-treatment and studied for reactivity to anti-MUC-1 antibodyusing spot test. Although the eluates from the DCs pulsed with the MUC-1 peptide showed the reactivity tothe antibody, no reactivity was seen in those from the DCs pulsed with non-related peptides. The inducedCTLs using the MUC-1 peptide exhibited a strong cytotoxic activity against MUC-1-expressing target cellsin the 51Cr-release assay. A strong cytotoxic activity of the CTLs was observed against the MUC-1-transduced cell line, whereas there was a weak activity against the MUC-1 deficient parent cell line. Usingsynthetic peptides is thought to be useful to induce MUC-1 specific CTLs for the purpose of immunotherapeutictreatment of cancer.},
 pages = {19--27},
 title = {合成ペプチドを用いたMUC-1特異的細胞傷害Tリンパ球(CTL)の誘導},
 volume = {14},
 year = {1999},
 yomi = {サワイ, サトル and コンタニ, ケイイチ and ハナオカ, ジュン and モリ, アツミ}
}